These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 37108147)

  • 21. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
    Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
    Liu JM; Chen YT; Wu CT; Hsu WL; Hsu RJ
    Prostate; 2022 May; 82(7):809-815. PubMed ID: 35226371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
    Collier A; Ghosh S; McGlynn B; Hollins G
    Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
    Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
    J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
    Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
    Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.
    Gupta D; Lee Chuy K; Yang JC; Bates M; Lombardo M; Steingart RM
    J Oncol Pract; 2018 Oct; 14(10):580-587. PubMed ID: 30312560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
    J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
    Crawford ED; Moul JW
    Oncology (Williston Park); 2015 Jan; 29(1):55-8, 65-6. PubMed ID: 25592210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients.
    Lu YC; Huang CY; Yeh HM; Hong JH; Chang CH; Muo CH; Chung SD; Yang TK; Jaw FS; Chung CJ
    Sci Rep; 2019 Oct; 9(1):14231. PubMed ID: 31578427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
    Lu-Yao G; Nikita N; Keith SW; Nightingale G; Gandhi K; Hegarty SE; Rebbeck TR; Chapman A; Kantoff PW; Cullen J; Gomella L; Kelly WK
    Eur Urol; 2020 Feb; 77(2):158-166. PubMed ID: 31420248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
    Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
    Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Appropriateness and complications of androgen deprivation therapy for prostate cancer: Can we do better? A retrospective observational analysis from a referral center.
    Oderda M; Bertetto O; Barbera G; Calleris G; Falcone M; Filippini C; Marquis A; Marra G; Montefusco G; Peretti F; Gontero P
    Urologia; 2023 Feb; 90(1):100-108. PubMed ID: 36703243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.
    Kim DK; Lee HS; Park JY; Kim JW; Ha JS; Kim JH; Yang WJ; Cho KS
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1217-1226. PubMed ID: 33000338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.